Eisai currently works across Europe in the areas of Alzheimer’s disease, gastro-intestinal disorders, epilepsy, cervical dystonia and severe, chronic pain, and is moving into neurology, cancer and critical care with its development portfolio.

Eisai and Animal Testing

Eisai is a company committed to improving the lives of patients and their families through the rapid development of innovative medicines, and honours the legal requirement for animal testing as an essential part of this process. This testing is overseen and guided by an Institutional Animal Care and Use Committee (IACUC), which includes external specialists, and is properly and scientifically conducted with due consideration to the well-being of the animals, according to the 3R Principles of appropriate animal testing:

Understanding the future information for investors